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Pospitalized Patients With Atrial
ibrillation and a High Risk of Stroke Are
ot Being Provided With Adequate Anticoagulation
lbert L. Waldo, MD,* Richard C. Becker, MD,† Victor F. Tapson, MD,‡ Kevin J. Colgan, MA,§
or the NABOR Steering Committee
leveland, Ohio; Durham, North Carolina; and Oak Brook, Illinois
OBJECTIVES The purpose of this study was to determine both treatment gaps and predictors of warfarin
use in atrial fibrillation (AF) patients enrolled in a national multicenter study.
BACKGROUND The National Anticoagulation Benchmark Outcomes Report (NABOR) is a performance
improvement program designed to benchmark anticoagulation prophylaxis, treatment, and
outcomes among participating hospitals.
METHODS A retrospective cohort study of inpatients was performed at 21 teaching, 13 community, and
4 Veterans Administration hospitals in the U.S. Patients with an ICD-9-CM code for AF
(427.31) were randomly selected.
RESULTS Among the 945 patients studied, the mean age was 71.5 ( 13.5) years; 43% were 75 years
of age, 54.5% were men, and 67% had a history of hypertension. Most (86%) had factors that
stratified them as at high risk of stroke, and only 55% of those received warfarin. Neither
warfarin nor aspirin were prescribed in 21% of high-risk patients, including 18% of those with
a previous stroke, transient ischemic attack, or systemic embolic event. Age 80 years (p 
0.008) and perceived bleeding risk (p  0.022) were negative predictors of warfarin use.
Persistent/permanent AF (p  0.001) and history of stroke, transient ischemic attack, or
systemic embolus (p  0.014) were positive predictors of warfarin use, whereas high-risk
stratification was not.
CONCLUSIONS This study confirms the under-use of warfarin, but also adds to published reports in several
regards. It showed that risk stratification, the guidepost for treatment in international
guidelines, had little effect on warfarin use, and that age 80 years and AF classification
(permanent/persistent) are factors that influence warfarin use. (J Am Coll Cardiol 2005;46:
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.06.0771729–36) © 2005 by the American College of Cardiology Foundation
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ctroke is one of the leading causes of adult disability in the
.S. Presently there are 4.7 million stroke survivors living in
he U.S., with 15% to 30% of those being permanently
isabled. Stroke costs the U.S. $31 billion in direct costs and
20.2 billion in indirect costs annually. (1).
Atrial fibrillation (AF) is a strong, independent risk factor
or stroke because it is associated with formation of left
trial thrombi. With advancing age, AF becomes an in-
reasingly important cause of stroke, with a prevalence1%
n those less than 60 years old and 8% to 10% in those more
han 80 years of age (2–4). Each year, 60,000 strokes occur
mong 2.3 million Americans with this arrhythmia and
onsequential risk for stroke and systemic emboli. These
ncidences are predicted to more than double in the coming
ecades (5). Randomized, controlled trials (6–13) have
hown that anticoagulation with warfarin (international
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ad no role in the design or conduct of the study; nor in the collection, management,
nalysis, or interpretation of the data; nor in the preparation, review, or approval of
his manuscript. Dr. Waldo is a consultant to AstraZeneca; Dr. Becker is a consultant
o AstraZeneca; Dr. Tapson is a consultant to AstraZeneca and Aventis; Mr. Colgan
s a consultant to AstraZeneca.T
Manuscript received December 18, 2004; revised manuscript received June 8, 2005,
ccepted June 28, 2005.ormalized ratio [INR], 2 to 3) reduces the risk of ischemic
troke by about 68% in unselected patients with AF
14–16).
This study was performed to determine recent stroke
revention practices, including predictors of anticoagulation
tilization, for inpatients with a primary or secondary
iagnosis of AF. In addition, benchmarking was used to
rovide a stimulus for improving antithrombotic manage-
ent in hospitals, where needed.
ETHODS
atient selection. Patients included in this study were
rom hospitals participating in the National Anticoagulation
enchmark and Outcomes Report (NABOR) program
EPI-Q Inc., Oak Brook, Illinois). The NABOR was
esigned to evaluate anticoagulation practices among U.S.
ospitals and to provide benchmark data on performance
ndicators from which participating hospitals could develop
quality improvement strategy for antithrombotic therapy.
eventy-five hospitals were invited to participate in the
ABOR program, and the first 40 hospitals responding
ere selected. Potential participants were identified based
n referrals from professional societies, and also by random
election by region. Hospitals were classified as academic,
ommunity, or Veterans Administration (VA) facilities.
hose with a disproportionate share designation, based on
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Warfarin Use in Stroke Risk AF Patients November 1, 2005:1729–36heir providing care to a high proportion of patients receiv-
ng Medicare or Medicaid supplemental security income,
ere also identified. Because no personal health information
as collected, institutional review board approval versus
xemption was determined by individual participating
ospitals.
Lists of patients meeting inclusion criteria were generated
y each participating center for the study period of January
, 2002, through December 31, 2002. From these lists, 25
ecords from each participating center were selected ran-
omly for inclusion. One site was allowed to include
atients treated beginning in July 2000 to obtain the
equested number of records for that site.
ligibility. Patients’ records were eligible for inclusion in
he NABOR program based on ICD-9-CM codes after
ischarge. Included were patients discharged with a primary
r secondary diagnosis of AF (ICD-9-CM 427.31). Pa-
ients were excluded if they were 18 years old, were
dmitted from another acute care hospital where therapy
as already initiated, or were discharged to another acute
are hospital to continue treatment.
ata collection. Patients admitted in the target population
ad charts reviewed by hospital personnel to determine the
ollowing: demographics; risk factors on admission predis-
osing patients to bleeding or thromboembolic events;
herapy for prevention and treatment of thromboembolic
nd ischemic events; treatment selection and dosing of
arfarin and aspirin; hospital course; and 30-day readmis-
ion to the same facility.
Participating hospitals were required to designate a facil-
tator and to complete a training session for randomization
nd data collection procedures before patient selection.
edical records were selected using a random numbers
able, with the exception of sites that had inherent random-
zation capability in their medical record system. Chart
eview was performed on-site by health personnel from the
articipating institution. A standard data collection form
Abbreviations and Acronyms
AF  atrial fibrillation
AFASAK  Atrial Fibrillation Aspirin and
Anticoagulation study
BAATAF  Boston Area Anticoagulation Trial for
Atrial Fibrillation
CAFA  Canadian Atrial Fibrillation study
EAFT  European Atrial Fibrillation Trial
INR  international normalized ratio
NABOR  National Anticoagulation Benchmark and
Outcomes Report
SPAF  Stroke Prevention in Atrial Fibrillation
study
SPINAF  Stroke Prevention in Nonrheumatic Atrial
Fibrillation study
TIA  transient ischemic attack
VA  Veterans Administrationnd data dictionary defining each collected element was fsed. Once data were collected, the site facilitator supervised
ata entry into the NABOR data entry software. The
oftware was used to remove any patient identifying infor-
ation, validate the completeness and consistency of entry,
nd transmit the data via the internet or diskette to the
tudy center for analysis. On receipt by the study center,
ata were queried for any inconsistencies, and queries were
esolved with the site before data entry.
We stratified patients for risk of stroke (2,3). Those with
previous stroke, transient ischemic attack (TIA), or
ystemic embolus; history of hypertension; left ventricular
ysfunction; age 75 years; rheumatic mitral valve disease;
r prosthetic heart valve were stratified to high risk. Those
ith one risk factor, including age 65 to 75 years, diabetes
ellitus, or coronary artery disease were stratified to mod-
rate risk, but those with one or more of these risk factors
ere stratified to high risk. Patents 65 years of age and
ounger and with no cardiovascular disease were stratified to
ow risk.
nalysis. To analyze the impact of patient characteristics
nd stroke risk factors on AF treatment, we used a two-
taged analysis strategy. At the univariate stage, we analyzed
he following possible predictor variables of AF treatment:
ge, AF classification (first vs. recurrent event, paroxysmal
s. persistent/permanent event), AF stroke risk category
low, intermediate, high), history of stroke or TIA, and
leeding risk (history of aneurysm, neuropsychologic im-
airment, past bleeding episode or perceived fall risk) (17).
ach possible predictor was examined in relation to warfarin
se and no treatment using chi-square methodology. For
ight patients with missing documentation of previous
troke, TIA, or systemic embolic event in the medical
ecord, these parameters were assumed to be absent in
nivariate analysis.
Three logistic regression models were then run with
arfarin use as the dichotomous-dependent variable. In the
rst model, AF risk category, history of stroke, TIA, or
ystemic embolic event, AF classification, and bleeding risk
ere entered into the model as independent variables. In the
econd model, we replaced AF risk category with age. In the
hird model, we removed all extraneous variables to create a
arsimonious model predicting treatment with warfarin.
dds ratios and 95% confidence intervals were calculated.
nalyses were conducted using SPSS for Windows version
1.0 (SPSS Inc., Chicago, Illinois) and in a two-tailed
ashion, with level of significance set as 0.05.
ESULTS
atient characteristics. A total of 945 patients were in-
luded from 21 academic hospitals, 13 community hospitals,
nd 4 VA hospitals located in 28 states. Ten were dispro-
ortionate share hospitals. The mean age was 71.5 years, of
hich 43.3% were older than 75 years, and 54.5% were
ale. Hypertension was the most frequently reported riskactor for stroke (66.9%), in addition to coronary artery
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November 1, 2005:1729–36 Warfarin Use in Stroke Risk AF Patientsisease (42.1%), congestive heart failure (34.4%), and dia-
etes (22%). One in five (20.7%) reported a previous history
f stroke, TIA, or systemic embolic event (Table 1).
elationship of stroke risk classification to anticoagulant
reatment. Of the 945 patients studied, 86.1% were strat-
fied to high risk, 6.5% to moderate risk, and 7.4% to low
isk. Figure 1 shows the treatment by risk stratification. In
he high- and moderate-risk cohorts, only 54.7% and 54.1%
p  0.931), respectively, were treated with warfarin,
hereas 1 in 5 (20.6%) and 3 in 10 (29.5%) (p  0.06),
espectively, were untreated, receiving neither warfarin nor
spirin. Patients in VA hospitals more frequently received
arfarin in the high-risk cohort (68%) than patients in
cademic (53%) and community hospitals (53%) (p 
able 1. Atrial Fibrillation Patient Characteristics
Characteristics
All Patients
n  945
ean age (yrs) 71.5  13.5
ge range (yrs)
65 270 (28.6)
66–75 256 (27.1)
75 419 (44.3)
ender
Male 515 (54.5)
Female 430 (45.5)
ther clinical characteristics
Hypertension 632 (66.9)
CAD/atherosclerosis 398 (42.1)
CHF (LV dysfunction) 325 (34.4)
Diabetes 208 (22.0)
Stroke, TIA, or systemic embolus 196 (20.7)
Cigarette smoking 184 (19.5)
AMI history 144 (15.2)
Alcohol abuse 93 (9.8)
DVT or PE history 55 (5.8)
Prosthetic heart valve 33 (3.5)
Rheumatic mitral valve 21 (2.2)
Thyrotoxicosis 8 (0.8)
alues expressed as n (%) or mean  SD.
AMI  acute myocardial infarction; CAD  coronary artery disease; CHF 
ongestive heart failure; DVT  deep vein thrombosis; LV  left ventricular; PE 
ulmonary embolism; TIA  transient ischemic attack.igure 1. Treatment of atrial fibrillation by risk stratification. Diagonal-striped
oxes  aspirin; black boxes  no treatment..009). Fifty-two percent of high-risk patients in
isproportionate-share hospitals received warfarin, com-
ared with 56% in non–disproportionate-share hospitals
p 0.245). For the entire AF population, warfarin use was
imilar both during hospitalization (53.5%) and on dis-
harge (54.4%).
We analyzed the cohort with the highest annual stroke
vent rate (18), which includes AF patients with a previous
istory of stroke, TIA, or systemic embolic event. Of the
96 patients in this cohort, only 120 (61.2%) received
arfarin. Forty-one (20.9%) received only aspirin, although
t is not indicated in guidelines (2,3), and 35 (17.9%)
eceived no treatment.
Further analysis of those in the high-risk cohort (n 
14) was performed to determine possible rationale for not
rescribing warfarin. Fall risk was reported in 41.7%,
europsychological impairment in 16.8%, a past bleeding
pisode in 14.6%, peptic ulcer disease in 12.7%, and a
istory of aneurysm in 5.1%. However, none of these factors
ere reported as present in 43.1% of high-risk patients not
eceiving warfarin (Table 2).
elationship of type of atrial fibrillation to anticoagulant
reatment. Both classification and type of event were ex-
mined to determine their effect on treatment. There was
ery nearly an even distribution between those classified as
aroxysmal (51.4%) and those classified as persistent/
ermanent (47.9%), although six records could not be
able 2. Atrial Fibrillation—Analysis of Factors in the High-
isk-Not-Receiving-Warfarin Cohort Associated With
erceived or Actual Bleeding Risk
Factors Associated With Perceived or
Actual Risk of Bleeding
Frequency
n  814 (%)
all risk 339 (41.7)
europsychologic impairment 137 (16.8)
ast bleeding episode 119 (14.6)
eptic ulcer disease 103 (12.7)
neurysm history 42 (5.1)
one of these factors 351 (43.1)boxes  warfarin; dotted boxes  warfarin plus aspirin; vertical-striped
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Warfarin Use in Stroke Risk AF Patients November 1, 2005:1729–36lassified (Fig. 2). Patients with persistent/permanent AF
ere more often treated with warfarin than those with
aroxysmal AF (60.5% vs. 47.3%, p  0.01), despite having
similar proportion of patients with either a high or a
oderate risk of stroke (94% vs. 91.2%) (p  0.189). In the
aroxysmal cohort, those with a recurrent event were more
ften treated with warfarin than those with a first event
52.2% vs. 41.1%, p  0.01). However, in the persistent/
ermanent cohort, there was no significant difference in
arfarin use between recurrent and first events (60.8% vs.
9.6%, p  0.83). The same analysis was performed to
etermine the effect of classification and type of event for
hose receiving no treatment. No significant differences
ere found between persistent/permanent and paroxysmal
20.3% vs. 22.6%, p  0.51), nor in the paroxysmal cohort
etween recurrent and first event (21.7% vs. 23.9%, p 
.36), nor in the persistent/permanent cohort between
ecurrent and first event (19.8% vs. 22%, p  0.61).
herefore, classification and type of event were not predic-
ors of non-treatment in this univariate analysis.
elationship of age to anticoagulant treatment and
leeding risk. In determining the effect of age on the risk
f bleeding and treatment with warfarin, we analyzed three
ifferent age groups, 65, 65 to 75, and 75 years. Using
he perceived or actual bleeding risk factors for stroke
eferenced in Tables 2 and 3, the risk of bleeding increased
s age increased from 29% in those 65 years old to 40.5%
n those 65 to 75 years, and 63.1% in those 75 years (p 
.001, chi-square test). However, there were no significant
Figure 2. Flow chart of classification, typifferences in the warfarin treatment rates of 52.2%, 57.8%,nd 52.1%, respectively (p 0.315) (Fig. 3). There was also
o significant difference in the non-treatment rate between
ge groups (22.6% for65 years vs. 23.4% for 65 to 75 years
s. 20% for 75 years, p  0.33).
In attempting to find a decision point at which age
ffected the use of warfarin, we analyzed the differences
etween those 80 years old and those 80 years old. In
hose 80 years, the warfarin treatment rate was 56.7%
ersus 46% in those 80 years (p  0.01). However, the
erceived or actual risk of bleeding was also 1.7 times
reater in those80 years old (69.1% vs. 40.5%, p 0.001)
Fig. 3).
We also determined the overall effect of perceived or
ctual bleeding risk and the individual effect of each bleed-
ng risk factor on use of warfarin in the cohort 80 years of
ge. In this cohort, 64.8% receiving warfarin versus 72.7%
vent, and treatment for atrial fibrillation.
able 3. Use of Warfarin in Patients 80 Years of Age
Treatment Selection
Warfarin
n  128 (%)
No Warfarin
n  150 (%) p Value
erceived or actual risk of
bleeding
83 (64.8) 109 (72.7) 0.31
nalysis by risk factor
Fall risk 64 (50.0) 91 (60.7) 0.15
Neuropsychologic
impairment
26 (20.3) 35 (23.3) 0.97
Past bleeding episodes 13 (10.2) 21 (14.0) 0.30
Peptic ulcer disease 9 (7.0) 24 (16.0) .025
Aneurysm history 7 (5.5) 9 (6.0) 0.58
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November 1, 2005:1729–36 Warfarin Use in Stroke Risk AF Patientsot receiving warfarin (p  0.31) had a perceived or actual
isk of bleed. The only bleeding risk factor that was a
redictor for use of warfarin was peptic ulcer disease, with a
eported incidence of 7% in those receiving warfarin versus
6% in those not receiving warfarin (p  0.025) (Table 3).
redictors of warfarin use. Three logistic regression mod-
ls were then run with warfarin use as the dichotomous
ependent variable. In the first model, AF stroke risk
ategory; history of stroke, TIA, or systemic embolic event;
ype of AF; and perceived or actual bleeding risk were
ntered into the model (Table 4). The AF risk was chosen
or incorporation in the model a priori with input from the
tudy committee. Age was not added to the regression
odel, because age is a primary determinant of AF risk.
ncluding both in the model would introduce colinearity.
ersistent/permanent AF; recurrent AF; and history of
troke, TIA, or systemic embolic event each were indepen-
igure 3. Warfarin use and perceived or actual bleeding risk by age
istribution. Bleeding risk includes fall risk, neuropsychological impair-
ent, past bleeding episode, peptic ulcer disease, and aneurysm history.
Chi-square test for trend. **Chi-square. Ruled boxes  warfarin use;
lack boxes  perceived or actual bleeding risk.
able 4. Variables Associated With Treatment With Warfarin
Independent Variables
Odds
Ratio
95%
Confidence
Interval
p
Value
odel 1
Perceived or actual bleeding risk 0.515 (0.38–0.69) 0.001
Persistent/permanent AF 1.685 (1.28–2.20) 0.001
Recurrent AF 1.341 (1.01–1.77) 0.042
Stroke/TIA/embolic event 1.482 (1.02–2.15) 0.038
High-risk stratification 1.367 (0.93–2.00) 0.111
odel 2
Perceived or actual bleeding risk 0.711 (0.53–0.93) 0.001
Persistent/permanent AF 1.708 (1.30–2.23) 0.001
Recurrent AF 1.314 (0.99–1.74) 0.058
Stroke/TIA/embolic event 1.559 (1.08–2.25) 0.018
Age 80 yrs 0.678 (0.49–0.92) 0.013
odel 3
Perceived or actual bleeding risk 0.724 (0.54–0.95) 0.022
Persistent/permanent AF 1.799 (1.37–2.34) 0.001
Stroke/TIA/embolic event 1.586 (1.09–2.28) 0.014
Age 80 yrs 0.663 (0.48–0.90) 0.0081bbreviations as in Table 1.ent variables associated with increased likelihood of receiv-
ng warfarin. Perceived or actual bleeding risk significantly
ecreased the likelihood of warfarin treatment, but as also
ndicated in univariate analysis, high-risk stratification was
ot associated with warfarin treatment.
In the second model, we replaced the high stroke risk
tratification category with age because univariate analysis
uggested that advanced age, despite any other potential
ssociation with increased stroke risk, was a negative pre-
ictor of warfarin use. Indeed, age 80 years significantly
ecreased the likelihood of warfarin treatment (odds ratio
.678, 95% confidence interval, 0.49 to 0.92, p  0.013). In
his model, the addition of age mitigated a portion of the
mpact of bleeding risk, indicating potential confounding.
owever, perceived or actual bleeding risk remained a
ignificant negative predictor of treatment with warfarin
odds ratio, 0.711; 95% confidence interval, 0.53 to 0.093;
 0.001). Also in this model, recurrent AF was no longer
significant predictor, controlling for the remaining vari-
bles in the model. Therefore, in the third and final model,
e removed recurrent AF. The remaining variables in the
odel were each highly associated with warfarin use. Age
80 years and perceived or actual bleeding risk were
egative predictors of warfarin use, and persistent/
ermanent AF and history of stroke, TIA, or systemic
mbolic event were positive predictors of warfarin use.
ISCUSSION
umerous, well-done AF trials, published between 1989
nd 1996, have shown that warfarin is highly effective in the
revention of stroke and death caused by thromboembolism
6–13). Largely based on these studies, guidelines for the
se of warfarin in AF patients at risk of stroke (high- and
oderate-risk categories) have been published and are
idely accepted (2,3). This study, which was performed in
broad geographic and categorical cross section of U.S.
ospitals, showed some aspects of the under-use of warfarin
hat will help us understand barriers to primary and second-
ry prevention of stroke. In spite of the risk of stroke being
imilar for paroxysmal versus persistent/permanent AF, we
howed that classification guided the treatment decision for
arfarin, and it should not. We showed that age 80 years
as a negative predictor of warfarin use in the age group at
ighest risk of stroke. It was disappointing that stroke risk
tratification was not a predictor of warfarin treatment, with
he exception of a previous history of stroke, TIA, or
ystemic embolic event. And even in those with a previous
troke, TIA, or systemic embolic event, the non-treatment
ate of 18% was high.
omparison with warfarin use in other AF studies. The
rst large study of national patterns of warfarin use in AF
as performed by Stafford and Singer (19). Using data from
ational Ambulatory Medical Care Surveys, their study
howed that warfarin use in AF had improved from 7% in
980 to 1981 to 32% in 1992 to 1993. Likewise, non-
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Warfarin Use in Stroke Risk AF Patients November 1, 2005:1729–36reatment declined from 90% to 48%. They showed that a
rend of increasing warfarin use coincided with the publi-
ation of the Atrial Fibrillation Aspirin and Anticoagulation
AFASAK) study (6), the Stroke Prevention in Atrial
ibrillation (SPAF) study (7–9), the Boston Area Antico-
gulation Trial for Atrial Fibrillation (BAATAF) (10), the
anadian Atrial Fibrillation (CAFA) study (11), and the
troke Prevention in Nonrheumatic Atrial Fibrillation
SPINAF) study (12) between 1989 and 1992. Other
tudies have been performed in hospitals, long-term care
acilities, and health maintenance organizations, showing a
ange in warfarin use from 32% to 57% and non-treatment
rom 22% to 59% (Table 5).
Our results show a 54% warfarin use rate, a likely
uboptimal treatment rate of 25% with aspirin, and a 22%
on-treatment rate in hospitalized patients. It is worth
mphasizing that our study represents a broad sample of
ospitals across the U.S. and is not limited to academic
ospitals (Albers et al. [20]), hospitals within a one-state
eography (Antani et al. [21], Whittle et al. [22], Flaker et
l. [23]), patients within one hospital/clinic (Bradley et al.
24]), a selected classification of AF (Munschauer et al.
25]), or a Medicare population (Jencks et al. [26], Whittle
t al. [22], Flaker et al. [23]). It is important to note from
longitudinal perspective that despite variability in the
tudy populations, warfarin use seems to have reached a
lateau at approximately the 55th percentile, since the mid
990s.
Our population’s incidence of major risk factors, includ-
ng hypertension, coronary artery disease, congestive heart
ailure, and diabetes mellitus, was 67%, 42%, 34%, and 22%,
espectively, compared with Albers et al. (20) with 55%,
able 5. NABOR Study Results Comparison Published Atrial Fi
Study Period Published Studies Setting
980–1981 Stafford et al. (19) Ambulatory
992–1993 Stafford et al. (19) Ambulatory
990–1993 Antani et al. (21) Teaching hospitals and
ambulatory
992–1994 Albers et al. (20) Teaching hospitals
993–1994 Whittle et al. (22) Small rural hospitals
993–1994 Flaker et al. (23) Rural and urban
hospitals
993–1995 Gurwitz et al. (34) Long-term care
994–1995 Munschauer et al. (25) Hospitals
994–1996 Bradley et al. (24) Hospital and ambulato
996–1997 Go et al. (5) Large HMO
997–1998 McCormick et al. (36) Longterm care
997–2001 Brophy et al. (35) Ambulatory
998–2001 Jencks et al. (26) Hospitals
000–2002 NABOR results Teaching, community,
and VA hospitals
Warfarin use was 64% in ideal candidates. †Warfarin use was 53% in ideal candida
AF atrial fibrillation; HMO health maintenance organization; NABORNa0%, 39%, and 22%, respectively, and Go et al. (5) with r1%, 29%, 31%, and 17%. Interestingly, the incidence of
ypertension ranged from 32% to 58% in the AFASAK (6),
AATAF (10), CAFA (11), SPINAF (12), and SPAF III
9) trials compared with our 67% incidence. The signifi-
ance of this comparison is related to the findings of the
PAF III Writing Committee, who reported a 3.6% inci-
ence of primary events in a “low-risk” cohort with hyper-
ension versus a 1.1% much lower incidence of primary
vents in those without hypertension (27). Our high inci-
ence of hypertension magnifies the need for greater use of
nticoagulation in those who are hospitalized.
ffect of bleeding risk on anticoagulation. Those using
nticoagulation in AF patients must deal with the dilemma
hat increasing age increases the risk of both stroke and
emorrhage. This paradox is confounded by other risk
actors for bleeding, particularly those for intracranial hem-
rrhage, such as cerebrovascular disease and hypertension
28), the incidence of which also increases with age. In our
ohort, age 80 years and the occurrence of overall per-
eived or actual bleeding risk was not significantly different
etween those receiving and not receiving oral anticoagula-
ion, with the exception of peptic ulcer disease. However,
e wonder whether anticoagulation intensity, which has a
trong relationship to both stroke and hemorrhage (28,30),
ight be a consideration, although it does not seem to be
ore inherently difficult to maintain therapeutic INRs as
atients get older (31). Our findings may suggest that age
80 years, alone or in combination with another perceived
arrier, other than the commonly professed risk of hemor-
hage, is the reason that physicians less frequently prescribe
ral anticoagulation to those over 80 years of age.
It was striking that in those high-risk patients not
tion Anticoagulation Studies
Warfarin
Use (%)
Non-Treatment
(%) Study Population
7 90 AF, excluding atrial flutter
32 48 AF, excluding atrial flutter
23 59 Sustained or intermittent
non-rheumatic AF
41 22 AF, excluding mitral
stenosis or heart valves
47* 43 AF, Medicare population
34 45 Non-valvular AF,
Medicare population
32 43 AF, including U.S. and
Canada facilities
34† 42 Chronic AF
51 25 AF, VA population
54‡ Not reported Nonvalvular AF
42 32 AF
35 Not reported Nonvalvular AF,
VA population
57 Not reported AF, Medicare population
54 22 AF
arfarin use was 55% in patients with no contraindications.
Anticoagulation Benchmark and Outcomes Report; VA Veterans Administration.brilla
ryeceiving warfarin, 43% had no perceived or actual bleeding
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November 1, 2005:1729–36 Warfarin Use in Stroke Risk AF Patientsisk factors present. Conversely, fall risk was the most
requently reported bleeding risk factor and was present in
1.7% of the population. If one accepts the conclusion of
an-Son-Hing and Laupacis (17) that the risk of subdural
ematoma from falling is remarkably small, then for most of
hese patients the benefits of anticoagulant therapy out-
eigh the risks. Therefore, the actual percent of patients not
eceiving warfarin who were appropriate candidates for
nticoagulation might more realistically approximate 62%,
hich represents those with no perceived or actual bleeding
isk other than the risk of fall.
redictors of warfarin use. This study points to an addi-
ional factor, aside from the commonly reported factors of
revious stroke, bleeding history, or increasing age, as being
redictive of warfarin use. A classification of persistent/
ermanent AF was associated with a 1.8-fold increase in the
dds of receiving warfarin. Others have not analyzed this
ffect, perhaps because analyses of trial data have indicated
hat the rate of stroke is similar for both paroxysmal and
hronic atrial fibrillation (32,33).
Go et al. (5), Antani et al. (21), Gurwitz et al. (34), and
rophy et al. (35) each analyzed positive and negative
redictors for warfarin use in their respective studies of AF.
hey also noted the relationship of such factors as previous
troke, advanced age, and risk of hemorrhage predicting the
se or non-use of warfarin. To our knowledge, we are the
rst to analyze and report persistent/permanent AF as a
redictor of warfarin use.
In an era of international guidelines, we would expect that
isk stratification for a high risk of stroke would have been
redictive of warfarin use. However, the slight trend ob-
erved was not statistically significant. Likewise, McCor-
ick et al. (36) in a study of long-term care patients showed
hat the odds of receiving warfarin increased with increasing
umber of stroke risk factors present, although this did also
ot reach statistical significance.
tudy limitations. Composition of the participating hos-
itals was a potential source of bias, with respect to our
ndings being representative of U.S. hospitals. Academic
ospitals contributed 55% of the study population, whereas
ommunity and VA hospitals contributed 34% and 11%,
espectively. In addition, we identified patients only by
CD-9-CM code, and did not require confirmation of a
iagnosis by an interpretable electrocardiogram. Others
ave noted the potential for misdiagnosis because of incor-
ect computerized interpretation of electrocardiogram, com-
ined with failure of the ordering physician to correct the
rroneous interpretation (37). We did not collect patient
reference data regarding the use of warfarin from notations
hat might have been made in the medical record. We also
id not exclude patients who had had open-heart surgery, a
roup in which AF is often transient. Another limitation is
hat our data lack information on use of warfarin after
ospital discharge, because many chronic medications are
ot necessarily initiated in the hospital setting. However, we
elieve that when indicated, it is usual practice to initiatearfarin therapy at the first opportunity. Thus, we would
ave expected that in most instances, warfarin therapy
ould have been initiated in the hospital, and continued on
n out-patient basis, making indicated dose adjustments
ntil a stable INR in the therapeutic range was achieved.
lso, the data were presumably from 2002, and in that
ense, not totally contemporary. However, importantly, the
merican College of Cardiology/American Heart Associa-
ion/European Society of Cardiology guidelines (3) were
ublished in September 2001, making these data uniquely
imely.
onclusions. Most hospitalized AF patients have a high
isk of stroke, particularly cardioembolic stroke. Data show
hat warfarin reduces the risk of cardioembolic stroke.
owever, warfarin is only used between 50% and 60% of the
ime in those AF patients with the greatest stroke risk.
ontraindications to warfarin do not account for this level
f under-use. Despite landmark clinical trials showing the
enefits of warfarin to prevent stroke, the level of non-
reatment and suboptimal treatment observed reflects either
he real-world limitations of warfarin, disregard for risk-
uided treatment, or both.
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